[Hypertensive patients treated with tielinic acid. A retrospective study of 298 cases (author's transl)].
Two-hundred and ninety-eight hypertensive patients received tielinic acid for a period of 4 to 42 months; in 295 cases the drug was combined with a potassium-sparing diuretic. No significant changes in mean serum creatinine levels were observed in the whole group. The slight rise in serum creatinine which occurred in 17 patients cannot be ascribed with certainty to the combined treatment. Two patients developed cytolytic hepatitis, and of the 253 patients whose serum transaminase levels were systematically measured, 18 had moderately increased levels; here again, the responsibility of the drug could not be fully established. These data suggest that combining tielinic acid with a potassium-sparing diuretic carries little risk of renal impairment and that this treatment can safely be used. The risk of liver damage is unquestionable but probably small no greater than that of other commonly used hepatotoxic drugs, notably allopurinol.
D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D006016:Glycolates / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D008297:Male; D012189:Retrospective Studies; D013989:Ticrynafen / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000637:Transaminases / Q000097:blood
D006016:Glycolates; D003404:Creatinine; D000637:Transaminases; D013989:Ticrynafen
Hypertendus traités par l'acide tiénilique. Etude rétrospective de 298 observations.